AD109 Pill Demonstrates Efficacy in Phase 3 Trial for Obstructive Sleep Apnea

The SynAIRgy phase 3 trial, presented at the 2026 American Thoracic Society International Conference and published in *American Journal of Respiratory and Critical Care Medicine*, enrolled 646 adults with mild-to-severe obstructive sleep apnea (OSA) across 69 sites in the United States and Canada. All participants were either unable to tolerate continuous positive airway pressure (CPAP) or had elected not to use it. Over six months, patients receiving the once-nightly oral combination of aroxybutynin and atomoxetine (AD109) experienced a 44 % reduction in the apnea-hypopnea index, compared with an 18 % reduction in the placebo group. More than 40 % of treated participants shifted to a lower OSA severity category, and 18 % achieved complete disease control. Secondary measures showed improvements in the oxygen desaturation index and overall hypoxic burden.

SciTechDaily

CPAP remains the standard OSA therapy, yet adherence rates are low because many patients find the device uncomfortable. AD109 targets the neuromuscular mechanisms that cause airway collapse during sleep, offering a pharmacologic alternative that does not require a mask or machine.

SciTechDaily

The trial’s first author, Dr. Patrick John Strollo, a sleep-medicine physician at the University of Pittsburgh Medical Center, led the clinical investigation. The study was conducted by the SynAIRgy investigators and sponsored by Apnimed, the developer of AD109.

SciTechDaily

In addition to respiratory improvements, the safety assessment identified dry mouth, nausea, insomnia, and difficulty urinating as the most common adverse events. Approximately 21 % of participants discontinued AD109 because of side effects. The overall safety profile was described as acceptable, with most events classified as mild and expected for the drug class.

SciTechDaily

Dr. Strollo emphasized that the trial’s outcomes align with emerging understanding of OSA biology and suggest that targeting neuromuscular dysfunction can produce clinically meaningful benefits. He also noted that the results complement a companion mechanistic review published in *American Journal of Respiratory Cell and Molecular Biology*, together providing an integrated view of disease pathways and therapeutic impact. Apnimed reported that AD109 has received FDA Fast Track designation for OSA and that a New Drug Application has been submitted. The company anticipates a potential PDUFA target action date in the first quarter of 2027, pending FDA acceptance of the application for review.

SciTechDaily

While efficacy signals are strong, the 21 % discontinuation rate highlights tolerability concerns. Critics argue that the side-effect profile may limit real-world adoption, especially among patients already managing comorbid conditions. Ongoing monitoring of long-term safety will be essential before widespread clinical use.

SciTechDaily

• “These results provide encouraging evidence that targeting neuromuscular dysfunction can translate into meaningful clinical outcomes, aligning with our evolving understanding of the disease biology,” — Patrick John Strollo, MD

SciTechDaily

• “In many other chronic diseases, such as cardiovascular disease, asthma, or type 2 diabetes, it would be unthinkable for the majority of diagnosed patients to remain untreated or undertreated. Yet that remains the reality in OSA,” — Patrick John Strollo, MD

SciTechDaily

• “An oral pill that targets the underlying neuromuscular drivers of airway collapse during sleep could help address this gap and broaden the range of effective options for patients who remain untreated today.” — Patrick John Strollo, MD

SciTechDaily

• “Together, these peer-reviewed articles connect late-stage clinical outcomes with the biological mechanisms that drive the disease, targeted by the mechanism of action of AD109, providing a more complete and integrated view of OSA and strengthening confidence in the approach,” — Patrick John Strollo, MD

SciTechDaily

Apnimed’s NDA submission places AD109 on a fast-track regulatory pathway, with a projected FDA action date in early 2027. If approved, the pill could become the first pharmacologic therapy to address the neuromuscular basis of OSA, expanding treatment options for patients who cannot use CPAP.

SciTechDaily